Omniab, Inc. · NASDAQ:OABI
Omniab — Q1 2026 Earnings Presentation
22 slides from Omniab's earnings presentation, May 7, 2026
Slide 1: Q1 2026 Financial Results & Business Update
1 Q1 2026 Financial Results & Business Update Nasdaq: OABI May 7, 2026
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, including our financial guidance fo
Slide 3: Introduction
Omni > Introduction Matt Foehr
Slide 4: Highlights
4 Highlights Clinical-stage partner pipeline advancement driving value for our stakeholders OmniAb's novel technologies positioned to have important impacts on our business and our industry Building a strong foundation for xPloration® With a very strong start to the year, we are raising our 2026 rev
Slide 5: Novel Technology Launches
5 Novel Technology Launches INNOVATION CONTINUES TO DIFFERENTIATE OUR PLATFORM POWERED BY EVOLUTION: Dual modality (antibodies & peptides) NOVEL PLATFORMS PRODUCING HUMAN Opening new market opportunities SEQUENCE ANTIBODIES IN A CHICKEN HOST Ultralong CDRH3 domains Driving partner interest Impactful
Slide 6: Novel Technology Launches
6 Novel Technology Launches DIFFERENTIATED TECHNOLOGIES DIVERSIFY REVENUE OPPORTUNITIES PARTNER ACCESS PROGRAM PLATFORM OFFERING INCLUDES: Competitively-priced instrument Proprietary, single-use consumables Annual software subscription Maintenance contracts Deployed instruments performing well for o
Slide 7: Active Partners
7 Active Partners Number of Active Partners(1)(2) Partner Type 107 100 • 107 Active Partners as of 3/31/2026 n=107 • New licenses added in Q1 included Florida State University 50 Partner Location(3) Middle East 1% Asia • 8 of the 10 largest global pharma companies 21% are Active Partners(4) US 55% E
Slide 8: Active Programs
8 Active Programs Number of 500 Active Programs(1) Q1 Change in Active Programs • 409 Active Programs as of 409 9 409 3/31/2026 407 400 (7) • >98% of our Active Programs 300 have contracted future economics to OmniAb 200 • Over $3 billion in total contracted milestones(2) 100 • Average royalty rate
Slide 9: Active Clinical Programs and Approved Products
9 Active Clinical Programs and Approved Products Number of Active Clinical Programs and Approved Products(1)(2) • 32 active clinical programs and approved products as of 3/31/2026 32 30 • A second OmnidAb -derived program entered the clinic in Q1(3) • Continue to expect multiple new clinical entrant
Slide 10: Clinical and Commercial-Stage Partner Pipeline
Clinical and Commercial-Stage Partner Pipeline 10 (1)(2) AS OF 3/31/2026 ONLY PROGRAMS WITH DOWNSTREAM ECONOMICS ARE SHOWN Phase Phase Phase11 1/1b Phase 1/2 1/2 Phase 2 Phase 3 Registration Approved 1/1b Immunovant, Hanall CStone Pharmaceuticals, Pfizer, Zhikang Hongyi (Biocity) CessationTherapeuti
Slide 11: Upcoming Partner Program Clinical/Regulatory Events
Upcoming Partner Program Clinical/Regulatory Events 11 POTENTIAL EVENTS IN 2026(1) Potential Potential Clinical Data Events Regulatory Action/Market Entry Teva Vitiligo(2) 1H 2026 Immunovant 2H 2026 Salubris 2026 TEV-’408 Phase 1b IMVT-1402 SAL003 IL-15 Topline Results FcRn PCSK9 Difficult-to-Treat
Slide 12: Select Partner Programs to be Highlighted at ASCO
12 Select Partner Programs to be Highlighted at ASCO ASCO ANNUAL MEETING IS TAKING PLACE MAY 29TH TO JUNE 2ND M9140 CEACAM-5 ADC Precemtabart tocentecan (Precem-TcT, M9140), an anti-CEACAM5 antibody-drug conjugate (ADC), in patients with metastatic pancreatic ductal carcinoma (mPDAC): Results from t
Slide 13: Financial Updates
13 Financial Updates Kurt Gustafson
Slide 14: Q1 2026 Revenue
14 Q1 2026 Revenue $ in millions $16 xPloration $14.4 $12 • License and Milestone revenue increased due to an increase in milestone revenue License & $8 Milestone • Service Revenue increased slightly due to new ion channel service contracts $4.2 xPloration $4 License & Milestone Service Service Roya
Slide 15: Q1 2026 Costs and Operating Expense (GAAP)
15 Q1 2026 Costs and Operating Expense (GAAP) $ in millions $25 $23.0 $22.3 • R&D expense decreased primarily due to lower Other Write-off personnel expenses, share-based compensation $20 (non-cash) expense and external expenses associated with Other legacy small molecule ion channel programs G&A $1
Slide 16: Q1 2026 Cash Costs and Operating Expense (Non-GAAP)
16 Q1 2026 Cash Costs and Operating Expense (Non-GAAP) GAAP TO NON-GAAP RECONCILIATION $ in millions Q1 2025 Q1 2026 Variance Costs and operating expenses (GAAP) $23.0 $22.3 ($0.7) Less: Depreciation of property and equipment 1.0 0.6 (0.4) Less: Amortization of intangible assets 3.2 6.0 2.8 Less: St
Slide 17: Q1 2026 vs. Q1 2025 Financial Results
17 Q1 2026 vs. Q1 2025 Financial Results (in millions, except per share data) Q1 2025 Q1 2026 Variance License and milestone revenue $ 2.0 $ 12.0 $ 10.0 Service revenue 1.9 2.1 0.2 xPloration revenue 0.0 0.1 0.1 Royalty revenue 0.2 0.2 0.0 Total revenue 4.2 14.4 10.3 Cost of xPloration revenue 0.0 0
Slide 18: Balance Sheet
18 Balance Sheet (in millions) December 31, March 31, 2025 2026 ASSETS Current assets: Cash & investments $ 54.0 $ 49.1 Accounts receivable, net 7.4 12.6 Other current assets 3.9 3.4 Goodwill & intangible assets 209.1 203.1 PPE & leases 25.0 24.1 Other assets 1.5 1.4 Total assets $ 300.9 $ 293.7 LIA
Slide 19: Updated 2026 Guidance
19 Updated 2026 Guidance • We now expect Total Revenue to be in the range of $28 to $33 million • We now expect Costs and Operating Expense to be in the range of $83 to $88 million • We continue to expect Cash Costs and Operating Expense (1) to be in the range of $50 to $55 million • We now expect y
Slide 20: Strong Financial Performance
20 Strong Financial Performance UPDATE TO 2026 GUIDANCE in millions Costs & Cash Costs & Revenue Operating Expense Operating Expense(1) Cash Use $28-$33 $100.9 $34 $40 $38.9 $100 $100 $25-$30 $87.6 $83-$88 $33.3 $80-$85 $26.4 $60.3 $19-$24 $18.7 $50-$55 $50-$55 $51.7 $16-$21 $17 $50 $50 $20 $0 $0 $0
Slide 21: Q&A
Omni Q&A
Slide 22: Omni
Omni >